secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024472
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial
----------------------------------------------------------------------

- Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).
- Cash and short-term investments $338.8M at Sep 30, 2022, down from $375.0M at Dec 31, 2021.
- First patient dosed with JANX007 in Phase 1 trial for prostate cancer; interim data expected 2H 2023.
- IND for EGFR-TRACTr (JANX008) on track for 2H 2022; PD-L1xCD28 TRACIr (JANX009) IND planned for 2023.
- Strengthened management with new HR head and board addition Winston Kung.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/0000950170-22-024472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022024472/janx-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer